title: Cost-effectiveness of positron emission tomography/computed tomography in the management of advanced head and neck cancer.
abstract: BACKGROUND
  Positron emission tomography/computed tomography (PET/CT) is a newer imaging modality that combines whole-body PET using [(18)F]fluorodeoxyglucose (FDG) and contrasted high-resolution CT. This has the advantage of combining the functional imaging of FDG-PET with the anatomic detail afforded by CT.
  
  
  OBJECTIVE
  To assess the cost-benefit of whole-body PET/CT as a diagnostic tool in head and neck cancer.
  
  
  METHODS
  A retrospective cohort (American Joint Committee on Cancer III-IVB squamous cell carcinoma in 2003) was reviewed for costs of diagnostic tests, distant metastases, and treatment type. This was compared to a hypothetical cohort of patients using PET/CT as a sole diagnostic tool using the current literature on test characteristics in the detection of distant metastases. The main outcome measure was the cost of the diagnostic workup, and the secondary outcome measure was the cost of the treatment.
  
  
  RESULTS
  The cost of the traditional workup was $450 per patient, whereas the cost of PET/CT workup was $722 per patient. The sensitivity of the traditional workup for lung metastases at 12 months was 14.3%. The average cost of curative surgery was $81,290, radiotherapy was $8,224, and chemotherapy was $1,158. In the cohort of 76 patients reviewed, improved PET/CT sensitivity would theoretically detect three more cases of metastatic disease and reduce the total cohort cost of treatment by $198,526 by relegating these patients to palliation.
  
  
  CONCLUSIONS
  PET/CT is a more expensive test when used alone in the diagnostic workup of head and neck cancer but results in an overall cost savings by reducing the number of futile radical treatments. There is a cost benefit to the use of PET/CT as the diagnostic and staging test for head and neck cancer patients.
authors.affiliation: Department of Surgery, University of Alberta, Edmonton, AB.
authors.forename: George
authors.initials: G
authors.lastname: Kurien
authors.forename: Jia
authors.initials: J
authors.lastname: Hu
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Harris
authors.forename: Hadi
authors.initials: H
authors.lastname: Seikaly
mesh_terms: D000368:Aged; D000416:Alberta; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000191:economics* / Q000473:pathology / Q000628:therapy; D015331:Cohort Studies; D003287:Contrast Media; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D005260:Female; D019788:Fluorodeoxyglucose F18; D017721:Hospital Costs; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000191:economics / Q000556:secondary / Q000628:therapy; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging / Q000191:economics*; D009367:Neoplasm Staging; D010039:Otorhinolaryngologic Neoplasms / Q000175:diagnosis* / Q000191:economics* / Q000473:pathology / Q000628:therapy; D010166:Palliative Care / Q000191:economics; D049268:Positron-Emission Tomography; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed; D051598:Whole Body Imaging / Q000191:economics
chemical_list: D003287:Contrast Media; D019788:Fluorodeoxyglucose F18